MIR19B1 (MicroRNA 19b-1)

Our findings indicate that circulating EV miRNAs in glioblastoma patients are associated with specific gene expression patterns in peripheral immune cells, suggesting a complex regulatory balance between pro-inflammatory and anti-inflammatory cues, potentially preceding full tumor-associated macrophage polarization. These molecular interactions may offer opportunities for developing early biomarkers or new therapeutic approaches.

Our findings reveal that miR-19b-3p orchestrates tumor-endothelial interactions by synchronously promoting EMT and EndMT, thereby driving a pro-metastatic microenvironment. Circulating miR-19b-3p represents a promising biomarker and potential therapeutic target in metastatic colorectal cancer.

As a pilot analysis, this work establishes a foundation for future prospective studies in larger, independent cohorts-including relevant disease control populations-to further define clinical performance, specificity, and utility in diagnostic and monitoring settings. Collectively, these results represent an important step toward the translation of plasma-based miRNA profiling into clinical application for GBM.

Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.

The RNA stability of lncRNA SNHG20 and HS3ST3B1 was tested after actinomycin D treatment...Further in vivo experiments also revealed that miR-19b-3p restrained the in vivo tumorigenicity of BCa cells and promoted apoptosis by suppressing the lncRNA SNHG20/HS3ST3B1 axis. In conclusion, overexpression of miR-19b-3p represses BCa cell proliferation and promotes apoptosis by suppressing the lncRNA SNHG20/HS3ST3B1 axis.

Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.

Additionally, we screened for potential small molecule inhibitors, identifying four promising candidates, including Dovitinib, S-Adenosylmethionine, Guanosine-5',3'-tetraphosphate, and Neomycin, which exhibited favorable drug-like characteristics. In conclusion, our multifaceted approach demonstrates the significant potential of LNA-anti-miR-19b-3p as a therapeutic option for TNBC patients, and the small molecule inhibitors we've uncovered could open new avenues for treating this aggressive form of breast cancer.

This compound demonstrated potential anticancer effects by modulating PI3K activity. The findings suggest that modulation of signaling pathways by natural compounds may represent a promising approach for development of novel cancer therapies.

The miRNA-mRNA network analysis identified hsa-mir-19b-3p as a key regulator of FAM3 genes, further implicating these genes in KIRC progression. This comprehensive analysis highlights the potential of FAM3 genes as biomarkers and therapeutic targets in KIRC.

Docking-based virtual screening suggests that budesonide, sirolimus, cephaeline, etoposide, and staurosporine may target proteins upregulated in GBM and ODG, such as APOC, MTHFD2, and LPL, in addition to their actual targets. Particularly, sirolimus and protriptyline exhibited comparable binding affinities against MTHFD2 (-11.23 kcal/mol) and LPL (-7.45 kcal/mol), respectively, compared to their actual targets. The holistic network-based approach applied in this study may be advantageous in the illumination of these subtypes and may aid in the design of improved therapeutics in treatment of the studied gliomas.

Our findings underscore the value of integrating exosomal biomarkers in liquid biopsies, highlighting their potential to improve early detection and monitoring of lung cancer development.